AD/PD 2026: Eisai highlights benefit of continued Leqembi treatment in early Alzheimer’s

On 18 March, Eisai presented four-year data from its OLE period of its Phase III CLARITY-AD trial of Leqembi to treat early Alzheimer’s. The post AD/PD 2026: Eisai highlights benefit of continued Leqembi treatment in early Alzheimer’s appeared first on Clinical Trials Arena .